慢阻肺患者应用双支扩剂加ICS治疗的临床效果分析

Clinical effect analysis of patients with chronic obstructive pulmonary disease treated with bronchodilator agent plus ICS

目的 为慢性阻塞性肺疾病(慢阻肺)患者实施双支气管扩张剂(双支扩剂)加吸入性糖皮质激素(ICS)治疗,分析其临床治疗有效性。方法 200例慢阻肺患者为研究对象,借助双色球抽取方法分为研究组与对照组,每组100例。对照组行常规治疗,研究组在对照组基础上行双支扩剂加ICS治疗。比较两组临床指标、肺功能指标[呼气流量峰值(PEF)、用力肺活量(FVC)、第1秒用力呼气容积(FEV1)]、炎症标志物[C反应蛋白(CRP)、降钙素原(PCT)]、治疗效果、不良反应发生率。结果 研究组患者的住院天数为(15.55±2.12)d,咳嗽天数为(4.25±3.22)d,肺部哮鸣音天数为(3.50±1.08)d;对照组患者的住院天数为(25.40±2.65)d,咳嗽天数为(6.75±1.06)d,肺部哮鸣音天数为(6.00±1.00)d。研究组的住院天数、咳嗽天数、肺部哮鸣音天数均短于对照组,存在显著差异(P<0.05)。治疗后,研究组患者的PEF、FVC、FEV1显著高于对照组,存在显著差异(P<0.05)。治疗后,研究组的CRP为(9.12±0.43)mg/L、PCT为(0.18±0.04)ng/ml,对照组的CRP为(15.80±2.08)mg/L、PCT为(1.23±0.11)ng/ml,研究组CRP、PCT更低,存在显著差异(P<0.05)。研究组患者总有效率为98.00%(98/100),对照组患者总有效率为73.00%(73/100),研究组总有效率高于对照组,存在显著差异(P<0.05)。研究组患者不良反应发生率为0.20%(2/100),对照组患者不良反应发生率为11.00%(11/100),研究组不良反应发生率低于对照组,存在显著差异(P<0.05)。结论 实施双支扩剂加ICS治疗,能够有效地改善慢阻肺患者的病情,降低了患者的炎症反应,延缓了病情进展,提高了患者的生活质量,值得推广和应用。

Objective To analyze the clinical effectiveness of bronchodilator agent plus inhaled corticosteroid(ICS)in the treatment of patients with chronic obstructive pulmonary disease.Methods 200 patients with chronic obstructive pulmonary disease were selected as the study subjects and divided into a study group and a control group by two-color sphere extraction method,with 100 cases in each group.The control group was treated with conventional therapy,and the study group was treated with bronchodilator agent plus ICS based on the control group.Both groups were compared in terms of clinical indicators,pulmonary function indicators[peak expiratory flow(PEF),forced vital capacity(FVC),forced expiratory volume in one second(FEV1)],inflammatory markers[C-reactive protein(CRP),procalcitonin(PCT)],therapeutic effect,and incidence of adverse reactions.Results In the study group,the hospitalization time was(15.55±2.12)d,the cough length was(4.25±3.22)d,and the lung wheezing time was(3.50±1.08)d;in the control group,the hospitalization time was(25.40±2.65)d,the cough length was(6.75±1.06)d,and the lung wheezing time was(6.00±1.00)d.The hospitalization time,cough length and the lung wheezing time of the study group were shorter than those of the control group,and there was a significant difference(P<0.05).After treatment,PEF,FVC and FEV1 of the study group were significantly higher than those of the control group,and there was a significant difference(P<0.05).After treatment,CRP and PCT in the study group were(9.12±0.43)mg/L and(0.18±0.04)ng/ml,and those in the control group were(15.80±2.08)mg/L and(1.23±0.11)ng/ml;CRP and PCT in the study group were lower.There was a significant difference(P<0.05).The total effective rate of the study group was 98.00%(98/100),and that of the control group was 73.00%(73/100).The total effective rate of the study group was higher than that of the control group,and there was a significant difference(P<0.05).The incidence of adverse reactions was 0.20%(2/100)in the study group and 11.00%(11/100)in the control group.The incidence of adverse reactions in the study group was lower than that in the control group,and there was a significant difference(P<0.05).Conclusion Bronchodilator agent plus ICS can effectively improve the condition of chronic obstructive pulmonary disease patients,reduce the inflammatory response of patients,delay the progression of the disease,and improve the quality of life of patients,which is worthy of promotion and application.